Characterisation of Uterine Fibroid Tissue Stiffness
Launched by DR. LINDA MCLEAN · Dec 8, 2017
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Aims and Objectives The goal of this project is to understand if and how uterine fibroid tissue stiffness, measured by SWE, can be used to predict and monitor response to medical therapy in patients with symptomatic uterine fibroids.
Aim 1: To assess the feasibility of using SWE for measuring stiffness of non-neoplastic myometrium and uterine fibroid tissue in pre-menopausal women Objective 1.1: Assess the inter- and intra-session reliability of measuring uterine tissue stiffness with SWE in 60 women with uterine fibroids and 60 healthy matched control participants.
Objective 1.2: Using d...
Gender
FEMALE
Eligibility criteria
- • Inclusion Criteria (All Participants)
- • Age 18 or older
- • Premenopausal
- • No co-morbidities known to impact tissue properties
- • Inclusion (FIB-Sx and FIB-Mx groups)
- • Diagnosis of fibroids by imaging (FIB-Mx and FIB-Sx groups)
- • Scheduled to undergo hysterectomy (FIB-Sx) or medical therapy (FIB-Mx) to treat symptomatic uterine fibroids
- • \<6 fibroids identified by medical imaging
- • Inclusion (CON group)
- • no known history of gynecological pathologies
- • regular menstrual cycles
- • Exclusion Criteria (All Participants)
- • confirmed or suspected uterine cancer
- • pregnancy
- • \<6months post-partum
- • history of caesarean delivery
- • previous uterine surgery
About Dr. Linda Mclean
Dr. Linda McLean is an esteemed clinical trial sponsor with a robust background in medical research and patient care. With a focus on advancing innovative therapies and improving clinical outcomes, Dr. McLean leads multidisciplinary teams in the design and execution of clinical trials across various therapeutic areas. Her commitment to ethical research practices and patient safety ensures that all trials are conducted with the highest standards of integrity and compliance. Dr. McLean's extensive experience in both academia and industry positions her as a key contributor to the advancement of medical science and the development of new treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ottawa, Ontario, Canada
Patients applied
Trial Officials
Linda McLean, PhD
Principal Investigator
University of Ottawa
Sukhbir S Singh, MD, FRCSC
Principal Investigator
The Ottawa Hospital Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials